Circulating CD62E+ Microparticles and Cardiovascular Outcomes by Lee, Soon-Tae et al.
Circulating CD62E
+ Microparticles and Cardiovascular
Outcomes
Soon-Tae Lee
1,2., Kon Chu
1,2., Keun-Hwa Jung
1,2, Jeong-Min Kim
1, Hye-Jin Moon
1, Jae-Jun Bahn
1, Woo-
Seok Im
1, Junsang Sunwoo
1, Jangsup Moon
1, Manho Kim
1,2, Sang Kun Lee
1,2, Jae-Kyu Roh
1,2*
1Department of Neurology, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea, 2Program in Neuroscience, Neuroscience Research
Institute of Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul, South Korea
Abstract
Background: Activated endothelial cells release plasma membrane submicron vesicles expressing CD62E (E-selectin) into
blood, known as endothelial microparticles (EMPs). We studied whether the levels of endothelial microparticles expressing
CD62E
+, CD31
+/Annexin-V
+, or CD31
+/CD42
2 predict cardiovascular outcomes in patients with stroke history.
Methods/Principal Findings: Patients with stroke history at least 3 months prior to enrolment were recruited. Peripheral
blood EMP levels were measured by flow cytometry. Major cardiovascular events and death were monitored for 36 months.
Three hundred patients were enrolled, of which 298 completed the study according to protocol. Major cardiovascular
events occurred in 29 patients (9.7%). Nine patients died, five from cardiovascular causes. Cumulative event-free survival
rates were lower in patients with high levels of CD62E
+ microparticles. Multivariate Cox regression analysis adjusted for
cardiovascular risk factors, medications and stroke etiologic groups showed an association between a high CD62E
+
microparticle level and a risk of major cardiovascular events and hospitalization. Levels of other kinds of EMPs expressing
CD31
+/Annexin-V
+ or CD31
+/CD42
2 markers were not predictive of cardiovascular outcomes.
Conclusion: A high level of CD62E
+ microparticles is associated with cardiovascular events in patients with stroke history,
suggesting that the systemic endothelial activation increases the risk for cardiovascular morbidities.
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Introduction
Endothelial activation or damage plays a pivotal role in
atherosclerosis [1,2]. Apoptotic and activated endothelial cells
release submicron vesicles called endothelial microparticles (EMPs)
from the plasma membrane. The level of these vesicles is a
sensitive indicator of the nature and extent of endothelial injury
and activation in coronary or peripheral artery diseases [3,4,5,6,7].
Elevated levels of EMPs, mostly defined as CD31
+/Annexin-V
+ or
CD31
+/CD42
2 microparticles, have been found in various
vascular disorders [8–13]. Moreover, EMPs accumulate in
atherosclerotic lesions and influence propagation of atherosclerosis
[14].
However, the role of EMPs in the prognosis of cardiovascular
diseases remains to be determined. Several different markers are
used to identify EMPs, and each marker has different clinical
implications. For example, apoptotic endothelial cells shed EMPs
in which constitutive markers such as CD31
+/Annexin-V
+
predominate, whereas activated endothelial cells shed EMPs in
which inducible markers such as CD62E (E-selectin) predominate
[4]. Thus, when endothelial cells were activated by tumor necrosis
factor-a to express surface adhesion molecules which participate in
leukocyte and platelet recruitments, the activated endothelial cells
release CD62E
+ microparticles [4]. Meanwhile, apoptotic endo-
thelial cells induced by growth factor deprivation release Annexin-
V
+ expressing microparticles [4]. In stroke patients, higher level of
circulating CD31
+/Annexin-V
+ microparticles is associated with
increased risk of intracranial stenosis, whereas higher level of
CD62E
+ microparticles is associated with extracranial carotid
atherosclerosis [8]. In pulmonary hypertension, an elevated level
of only CD62E
+ microparticles is predictive of a poor outcome
[15]. Finally, in obstructive sleep apnea, continuous positive
airway pressure therapy reduces the level of CD62E
+ but not
CD31
+/CD42
2 microparticles [16].
Given this evidence, we hypothesized that the higher level of
CD62E
+ microparticles could be useful for predicting the poor
cardiovascular prognosis of non-coronary artery diseases. We also
hypothesized that microparticles expressing CD31
+/Annexin-V
+
or CD31
+/CD42
2 might have limited but still meaningful
predictive values for the poor cardiovascular prognosis as well.
We therefore performed a prospective study in which we
examined the association between the level of endothelial
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stroke.
Methods
Subject enrollment
This study was approved by the institutional review board of
Seoul National University Hospital, and all subjects provided
written informed consent prior to enrollment. Patients who
experienced a first-ever stroke at least 3 months prior to enrolment
were recruited at the Stroke Clinic of the Department of
Neurology, Seoul National University Hospital. Because several
conditions are known to increase the level of EMPs, subjects were
excluded if they had one of the following: symptomatic coronary
artery disease, symptomatic peripheral artery disease, or stroke of
other determined etiology such as nonatherosclerotic vasculopathy
and hypercoagulable states. We have previously reported that
patients with recent stroke have high levels of EMPs [8], and those
with recent stroke within the 3 months before enrolment were
excluded in the current study.
Subject assessments
At enrolment, citrated whole blood (5 ml), demographic data,
and medical history were collected from each patient. The total
cardiovascular risk factor burden at baseline was calculated for
each patient using Framingham risk factor scores [17]. Stroke
etiologies at baseline were determined according to the TOAST
classification [18]. All patients were followed-up every 3 to 6
months for 36 months to collect information about the occurrence
of the following outcomes: first major cardiovascular event,
including acute myocardial infarction or new coronary artery
disease, stroke, hospitalization due to cardiovascular events,
revascularization procedure, and death from cardiovascular
causes; acute myocardial infarction and new coronary artery
disease; revascularization in coronary, peripheral, and cerebral
arteries; hospitalization due to cardiovascular events; ischemic or
hemorrhagic strokes; death from cardiovascular causes; and death
from any cause.
Measurement of EMP levels
EMPs were quantified as described previously [19]. Briefly,
citrated whole blood was centrifuged at 15006 g for 15 min to
prepare platelet-rich plasma. The platelet-rich plasma was further
centrifuged for 2 min at 13,0006g to obtain platelet-poor plasma,
which was stored at 270uC. The platelet-poor plasma was
thawed, and a 50-mL aliquot was mixed on an orbital shaker
(120 rpm) for 30 min at room temperature with phycoerythrin-
labeled anti-CD62E antibody (2 mL; BD Biosciences, San Jose,
CA) or with a mixture of phycoerythrin-labeled anti-CD31,
fluorescein isothiocynate-labeled anti-CD42b, and allophycocya-
nin-labeled Annexin-V antibody (2 mL each; BD Biosciences). The
samples were then diluted to 1 ml with phosphate-buffered saline
and analyzed with a FACS II flow cytometer (BD Biosciences) at
the medium flow-rate setting and a 30-second stop time. EMPs
were primarily defined as particles ,1 mm expressing CD62E.
Microbeads from a FACS Size Calibration Kit (Invitrogen,
Carlsbad, CA) were used for size calibration. Apoptotic EMPs
we defined as the sum of CD31
+Annexin V
+ and CD31
+/CD42
2
EMPs. Values are reported as counts/mL of platelet-poor plasma.
Calculations and statistical analyses
The patients were stratified into high and low groups according
to their levels of CD62E
+ microparticles, with each group
including 50% of the patients. The assumption of a normal
distribution was determined by Kolmogorov-Smirnov test. Differ-
ences between continuous values with a normal distribution were
analyzed by Student’s t-test. Differences between values with non-
normal distributions were analyzed by Mann-Whitney U test.
Differences between categorical variables were analyzed by chi-
square test. Univariate correlations between clinical factors and
EMP groups were assessed using Pearson’s correlation coefficients
for continuous values and Spearman’s correlation coefficients for
categorical values. Baseline demographic characteristics, stroke
etiologic groups, and medication use were analyzed using a
multiple logistic regression model to identify independent
predictors of cardiovascular outcomes. A multivariate Cox’s
proportional-hazards regression analysis was performed to deter-
mine the association between EMP counts and each outcome.
Analyses were adjusted for advanced age ($65 years); sex;
hypertension; diabetes; dyslipidemia; smoking; high cardioembolic
risk; coronary artery disease; treatment with antiplatelet agents,
anticoagulation, angiotensin converting enzyme inhibitors/angio-
tensin II receptor blockers, beta-blockers, calcium-channel block-
er, diuretics, or statins; and stroke etiologic groups. Survival was
determined by the Kaplan-Meier method and the log-rank test
was used to determine the statistical significance of differences in
event-free survival. Data are expressed as means 6 standard
deviations or as a number (percentages). SPSS software (SPSS
17.0, SPSS Inc., Chicago, IL) was used for analyses, and a two-
tailed probability value less than 0.05 was considered to be
significant. All investigators performing event classifications were
blinded to patients’ EMP levels.
Results
Baseline characteristics
Three hundred patients were enrolled. Two patients were lost to
follow-up before 36 months, so that 298 patients completed the
study according to protocol. The patient characteristics are
summarized in Table S1. At enrollment, the number of
CD62E
+ microparticles/mL ranged from 0 to 1223, with a mean
of 876128 (after common logarithmic transformation,
1.7460.38). Because levels of EMPs were not normally distributed
according to a Kolmogorov–Smirnov test (P,0.001), the patients
were stratified into two equal groups according to their levels of
CD62E
+ microparticles: counts/mL ranged from 0 to 53 for the
low CD62E
+ microparticle group and from 54 to 1223 for the high
CD62E
+ microparticle group. According to univariate analysis,
none of the baseline characteristics, risk factors, medication
profiles, and the mechanisms of previous stroke were significantly
associated with the level of CD62E
+ microparticles at enrollment
(Table S1). In addition, the level of CD62E
+ microparticle was not
correlated with the time from stroke onset (Figure S1).
Cardiovascular outcomes
At 36 months, nine patients (3.0%) had died, including five from
cardiovascular causes (1.7%), one from pneumonia, one from
renal insufficiency, one from prostate cancer, and one for an
unclassified reason (Table 1). Twenty-nine patients (9.7%) had
major cardiovascular events, including 11 (3.7%) that had an acute
myocardial infarction or new coronary artery disease, five (1.7%)
that required revascularization, and 23 (7.7%) that were admitted
to a hospital due to cardiovascular events. The incidences of a first
major cardiovascular event and of hospitalization were higher in
the high CD62E
+ microparticle group than in the low CD62E
+
microparticle group (P=0.011 and 0.017, respectively) (Table 1).
Microparticles and Cardiovascular Outcomes
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patient characteristics
Univariate analysis indicated an association between all major
cardiovascular events and advanced age (P=0.007), known
coronary artery disease (P=0.009), and a high CD62E
+
microparticle level (P=0.017). The incidence of myocardial
infarction and new coronary artery disease was associated with
known coronary artery disease (P=0.002). The incidence of
hospitalization was associated with advanced age (P=0.009),
known coronary artery disease (P=0.014), and a high level of
CD62E
+ microparticles (P=0.025). The incidence of stroke was
associated with the use of anticoagulants (P=0.034) and a lower
incidence of stroke with the use of calcium-channel blocker
(P=0.044). The incidence of ischemic stroke was significantly
associated with the use anticoagulants (P=0.047). Other cardio-
vascular outcomes, including the incidences of revascularization,
hemorrhagic stroke, death from cardiovascular causes, and death
from any causes were not significantly associated with demo-
graphic factors or the CD62E
+ microparticle level (data not
shown). Also, outcomes were not significantly associated with any
of the stroke etiologic groups (data not shown).
Multivariate regression analysis found that the occurrence of
major cardiovascular events was associated with a high level of
CD62E
+ microparticles (HR, 3.73; 95% CI, 1.39 to 10.07;
P=0.009), advanced age (HR, 3.36; 95% CI, 1.25 to 10.36;
P=0.018), coronary artery disease (HR, 4.70; 95% CI, 1.06 to
20.92; P=0.042), and the use of anticoagulants (HR, 10.23; 95%
CI, 1.56 to 66.92; P=0.015). The occurrence of hospitalization
was significantly associated with a high CD62E
+ microparticle
level (HR, 4.00; 95% CI, 1.25 to 12.48; P=0.019), advanced age
(HR, 4.44; 95% CI, 1.27 to 15.49; P=0.019), coronary artery
disease (HR, 5.13; 95% CI, 1.04 to 25.25; P=0.044), and the use
of anticoagulants (HR, 19.32; 95% CI, 2.60 to 143.50; P=0.004),
and a lack of hospitalization was significantly associated with the
use of calcium-channel blockers (HR, 0.28; 95% CI, 0.08 to 0.94;
P=0.039). The incidence of all stroke was significantly associated
with advanced age (HR, 4.07; 95% CI, 1.01 to 16.38; P=0.048)
and the use of anticoagulants (HR, 21.03; 95% CI, 2.45 to 180.64;
P=0.006), and a lack of stroke was associated with the use of
calcium-channel blockers (HR, 0.153; 95% CI, 0.03 to 0.77;
P=0.023). The incidence of ischemic stroke was significantly
associated with of the use of anticoagulants (HR, 13.14; 95% CI,
1.31 to 132.04; P=0.029). Other cardiovascular outcomes,
including the incidences of revascularization, hemorrhagic stroke,
death from cardiovascular causes, and death from any causes were
not significantly associated with any demographic factor, stroke
etiology group, or CD62E
+ microparticle level (data not shown).
High CD62E
+ microparticle and increased risks for all
major cardiovascular events and hospitalization
Cumulative event-free survival rates were higher in the low
CD62E
+ microparticle group for all major cardiovascular events
(P=0.013; Fig. 1) and hospitalization (P=0.018; Fig. 2). In
addition, univariate Cox regression analysis found that a high level
of CD62E
+ microparticles was significantly associated with an
increased risk for all major cardiovascular events and for
hospitalization due to cardiovascular events (Table 2). Multivariate
Cox regression analysis adjusting for advanced age, sex,
cardiovascular risk factors, concomitant drug therapies, and stroke
etiology groups, confirmed a significant association between a high
level of CD62E
+ microparticles and an increased risk of all major
cardiovascular events (Table 2). A high level of CD62E
+
microparticles was also significantly associated with an increased
risk of hospitalization.
CD31
+/CD42
2 and CD31
+/Annexin-V
+ microparticles
The number of CD31
+/Annexin-V
+ microparticles ranged
from 7 to 3684 (mean 6 standard error, 2136407), and the
number of CD31
+/CD42
2 microparticles ranged from 9 to 3902
(2326415). There was not a significant association between these
two measures and any of the baseline characteristics or with any of
the cardiovascular outcomes (data not shown). The levels of
CD62E+ microparticles were not correlated with the levels of
CD31
+/CD42
2 (Figure S2) or CD31
+/Annexin-V
+ microparticles
(Figure S3).
Discussion
Here, we showed that a high level of CD62E
+ microparticles is
associated with an increased risk of major cardiovascular events
and hospitalization in patients with old stroke. Because CD62E
+
microparticles are released from activated endothelial cells [4], our
results suggest that endothelial activation participates in the
pathogenesis of cardiovascular diseases and is likely to increase the
risk of subsequent cardiovascular morbidities. In addition,
Table 1. Frequency of cardiovascular events, hospitalization due to cardiovascular events, and death 36 months after enrollment.*
Events Total (N=298)
Low CD62E
+ microparticle
group (N=149)
High CD62E
+ microparticle
group (N=149) P-value{
All major cardiovascular events 29 (9.7) 8 (5.4) 21 (14.1) 0.011
Myocardial infarction or new CAD 11 (3.7) 3 (2.0) 8 (5.4) 0.124
Revascularization 5 (1.7) 1 (0.7) 4 (2.7) 0.176
Hospitalization{ 23 (7.7) 6 (4.0) 17 (11.4) 0.017
All stroke 17 (5.6) 6 (4.0) 11 (7.4) 0.212
Ischemic stroke 13 (4.4) 4 (2.7) 9 (6.0) 0.156
Hemorrhagic stroke 4 (1.3) 2 (1.3) 2 (1.3) 1.000
Death from cardiovascular cause 5 (1.7) 1 (0.7) 4 (2.7) 0.176
Death from any cause 9 (3.0) 3 (2.0) 6 (4.0) 0.310
*Values are numbers of patients in each category, with the percent of the total in the group in brackets. CAD denotes coronary artery disease.
{P values were determined by chi-square test.
{Hospitalization was due to cardiovascular events, including recurrent angina, congestive heart failure, myocardial infarction, and stroke.
doi:10.1371/journal.pone.0035713.t001
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+ EMP levels might be helpful for
identifying high-risk patients.
The current study is important because it shows a clinical
significance of EMPs in patients with stroke history, where few
markers of cardiovascular outcome have been identified. Several
markers of cardiovascular risk have been identified in normal
population or coronary diseases. For example, an increased
carotid artery intima-media thickness is a predictor of future
vascular events [20], an elevated homocysteine concentration is
associated with ischemic heart disease and stroke in healthy
populations [21], high C-reactive protein levels are associated with
an increased likelihood of cardiovascular events in women [22],
and the number of endothelial progenitor cells is predictive of
cardiovascular outcome in patients with coronary artery diseases
[23]. However, the etiologies of stroke include non-atherosclerotic
conditions, such as cardioembolism and hemorrhagic stroke, so
the cardiovascular prognosis of stroke patients is expected to differ
from that of patients with coronary artery diseases.
Although the patient population in this study was heterogeneous
with including all chronic stroke etiologies, it is representative of
what is typically encountered in the stroke clinic and therefore
clinically relevant. Because the classification of stroke etiologies
can be subjective [18], it is more clinically relevant than selecting
individual stroke etiologies. Stroke patients with an atherosclerotic
etiology often have co-morbidities of cardioembolism and
hemorrhagic stroke, further complicating determination of the
etiology. In our study, the use of anticoagulation was associated
with the higher recurrence of ischemic stroke. This is likely a
confounding effect because the patients with high risk factors for
cardioembolic stroke, such as atrial fibrillation, were treated with
anticoagulation, which could not totally ameliorate the develop-
ment of subsequent ischemic strokes.
The level of CD62E
+ microparticles is likely to be an indicator
of systemic endothelial pathology rather than of cerebral
atherosclerosis itself. This is because higher levels of CD62E
+
microparticles were associated with the occurrence of all major
cardiovascular diseases and of hospitalization, whereas they were
not associated with stroke recurrence. However, interpretation and
application of these results are limited by the relatively few
outcome events that were assessed and because all cardiovascular
events and hospitalization comprised most (.20) of the events that
occurred. Accordingly, larger studies with more outcome events
are needed to confirm the current findings and to extend them in
non-stroke populations.
In this study, we enrolled patients who experienced a first-ever
stroke at least 3 months prior to enrolment. According to a
previous study, newly-generated microparticles are cleared within
10 min from the circulation [24]. Our previous data also showed
that the level of EMPs is increased acutely after ischemic stroke
and normalized in six days [8]. In the current study, the mean
level of CD62E
+ microparticles in the patients with previous old
stroke was 1.7560.40 (common logarithmic transformed), which is
similar to the normal level of CD62E
+ microparticles in subjects
without previous stroke [8]. In addition, there was no correlation
between the level of CD62E
+ microparticles and the time since old
stroke onset in the current study. Accordingly, EMPs remain very
shortly in the blood, and there must be continuous microparticle
production in the high microparticle group. Follow-up measure-
ment of the EMP levels at the end of the study might have
provided additional information.
Our results suggest that endothelial activation plays a more
important role than apoptosis in the worsening of the cardiovas-
cular condition in patients with stroke history. Unlike the level of
CD62E
+ microparticles, the level of CD31
+/Annexin-V
+ apoptot-
ic microparticles was not predictive of cardiovascular outcomes.
This contrasts with previous reports that, in patients with coronary
artery diseases, the high level of circulating CD31
+/Annexin-V
+
microparticles correlates with impairment of coronary endothelial
function or future cardiovascular events [25,26]. The differences
between these results and ours are probably due to different
endothelial responses underlying stroke and coronary artery
disease. When endothelial cells undergo apoptosis, the EMPs
released predominantly bear constitutive markers such as CD31
and Annexin-V, whereas activated endothelial cells release EMPs
in which inducible markers such as CD62E predominate [4].
CD62E is a member of the selectin family of adhesion molecules
expressed primarily on activated vascular endothelium and
facilitates the rolling and adhesion of inflammatory cells [4,27].
Our previous study also showed that patients with extracranial
Figure 1. Cumulative event-free survival according to all
cardiovascular events stratified by the level (low, high) of
circulating CD62E
+ microparticles at enrollment.
doi:10.1371/journal.pone.0035713.g001
Figure 2. Cumulative event-free survival according to hospi-
talization stratified by the level (low, high) of circulating
CD62E
+ microparticles at enrollment.
doi:10.1371/journal.pone.0035713.g002
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+ microparticles than
those without the stenosis, while CD31
+/Annexin-V
+ micropar-
ticles was associated with intracranial stenosis [8]. Therefore, the
surface marker for detecting EMPs must be chosen according to
the characteristics of patient population.
The precise function of CD62E
+ microparticles remains to be
determined. EMPs are likely to be involved in the pathogenesis of
cardiovascular diseases by promoting inflammation, vascular
dysfunction, and coagulation [5]. EMPs impair endothelium-
dependent relaxation by regulating the endothelial nitric oxide
transduction pathway [28–30], by expressing prothrombotic tissue
factor activity [31], and by disseminating proadhesive and
procoagulant factors in thrombotic disorders [32]. In addition,
EMPs act as vectors for transcellular messages that regulate
vascular function [5], and they mediate the activation of
endothelium-leukocyte crosstalk by stimulating procoagulant
properties of leukocytes [33]. Our current findings suggest that
the extent of endothelial cell activation is an indicator of the active
pathogenesis of cardiovascular disease. Further improvements in
the EMP assay may allow non-invasive, real-time monitoring of
vascular endothelial responses and the effects of medicines that
prevent vascular damage.
Supporting Information
Figure S1 Correlation plots between CD62E
+ levels and
time since stroke onset. (A) The two variables were not
correlated each other (Pearson’s correlation coefficient=0.057,
P=0.327). CD62E
+ levels are counts/mL of platelet-poor plasma.
(B) Even after common logarithmic transformation, the level of
CD62E microparticles was not correlated with the time since
stroke onset (Pearson’s correlation coefficient=0.065, P=0.262).
(TIF)
Figure S2 Correlation plots between CD62E
+ and
CD31
+/CD42
2 microparticles. The two measurements were
not correlated each other (Pearson’s correlation coeffi-
cient=0.040, P=0.487). Values are counts/mL of platelet-poor
plasma.
(TIF)
Figure S3 Correlation plots between CD62E
+ and
CD31
+/Annexin-V
2 microparticles. The two measurements
were not correlated each other (Pearson’s correlation coeffi-
cient=0.028, P=0.636). Values are counts/mL of platelet-poor
plasma.
(TIF)
Table S1 Baseline characteristics of the patients.
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